49 results about "Uncoupling protein" patented technology

The present invention relates to methods for prevention and / or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.

Brown adipose tissue (“BAT”) progenitor cells and methods for identifying BAT progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of BAT progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of BAT uncoupling protein-1 (“UCP1”), and for identifying agents capable of inducing differentiation of BAT progenitor cells into brown adipocytes and / or inducing expression or increased activity levels of UCP1. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for treatment of or the making of medicaments for the treatment of metabolic diseases or conditions in a patient such as obesity, overweight, impaired glucose tolerance, insulin-resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, metabolic syndrome, and the like. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for prevention of hypothermia.

Genipin derivatives and pharmaceutical compositions thereof that inhibit the activity of uncoupling protein-2 (UCP2) and are useful in treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemia in a mammal are disclosed.

The invention discloses new application of axitinib. Axitinib can be used for preparing medicine for promoting white fat cell browning and used for preventing and treating obesity and diseases related to obesity. The medicine can promote primary white fat cell browning in vitro, thereby enhancing expression of brown fat cell marker gene uncoupling protein 1 (UCP1), and can promote the increase of beige fat cells in white fat tissue of groin and the increase of expression of UCP1; the medicine can resist obesity and insulin insensitivity caused by high-fat diet and has an effect on treating fatty livers.

The present invention relates generally to compositions and methods for the treatment of body weight disorders including, but not limited to, obesity. More specifically, the present invention relates to nucleic acids encoding a human UCP2 polypeptide; a human UCP2 polypeptides encoded by such nucleic acids; recombinant nucleic acid molecules containing nucleic acids encoding a human UCP2 polypeptide; cells containing such recombinant nucleic acid molecules; a method for producing human UCP2 polypeptides; and methods for detecting modulators of UCP2 gene expression and UCP2 polypeptide expression.

The invention is based in part on the discovery that uncoupling proteins (UCPs) are expressed in the plasma membrane of rapidly dividing cells but not of growth arrested, chemotherapy resistant cells. It has also been found according to the invention that UCP is expressed in the lysosomal membrane under certain metabolic conditions. Thus the invention is methods, products, screening assays and kits relating to the manipulation of UCP expression within cellular and intracellular membranes.

The invention is based in part on the discovery that uncoupling proteins (UCPs) are expressed in the plasma membrane of rapidly dividing cells but not of growth arrested, chemotherapy resistant cells. It has also been found according to the invention that UCP is expressed in the lysosomal membrane under certain metabolic conditions. Thus the invention is methods, products, screening assays and kits relating to the manipulation of UCP expression within cellular and intracellular membranes.

The invention discloses a non-human mammal model with an input UCP1-1cuiferase (uncoupling protein 1-1cuiferase) gene as well as a construction method and the application of the non-human mammal model. The constructed non-human mammal model with the input UCP1-1cuiferase gene can be taken as a screening platform of white fat cell brownness drugs, and the simple, rapid and large-scale screening on drugs for regulating and controlling the expression of the UCP1 can be realized; on the premise that non-human mammal is not hurt, the expression and distribution of the UCP1 can be directly subjected to bio-assay by utilizing a fluorescent imager.

The physiological regulation of intake, growth and energy partitioning in animals is under the control of multiple genes, which may be important candidates for unraveling the genetic variation in economically relevant traits in beef production. The present invention relates to the identification of a single nucleotide polymorphisms (SNPs) within the bovine genes encoding growth hormone receptor (GHR), ghrelin, leptin, neuropeptide Y (NPY), and Uncoupling Protein 2 (UCP2) and their association with economically relevant traits in beef production. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable meat quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field locations.

A nucleotide sequence of hog uncoupling protein gene 2 and the method for testing its polymorphism are disclosed. Said nucleotide sequence, SEQ ID No.3, can code the hog UCP2 protein, is the sequence in the segment 3-4 of hog UCP2 exon and the segment 3 of intron, and has 89% homology with the nucleotide sequence of human relative sequence. It can be used to research the growth and energy conversion of hog.

The invention provides a sheep UCP1 (uncoupling protein 1) allelotype detection kit which comprises a specific primer pair and sheep UCP1 allelotype standard DNAs, wherein the specific primer pair comprises a sense primer 5'-AGATACAAGCGGAAGAGACAC-3' and an antisense primer 5'-TGAAGGGTTGGGTCTGTCA-3'; the sheep UCP1 allelotype standard DNAs are SEQ ID No. 1-3 in a sequence table. The invention further provides a sheep UCP1 allelotype detection method. By the detection method, different sheep UCP1 allelotypes and sheep carcass fat content characters are associatively analyzed, and researches show that a sheep UCP1 allelotype has remarkable influence (P<0.05) on a carcass fat content character of a sheep population. Therefore, a sheep UCP1 gene can be determined to improve the sheep carcass fat content character as a molecular marker.

The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and / or uncoupling protein 1 (Thermogenin / Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.

The invention discloses a method for constructing a genetic engineering cell strain of an obesity-resistant medicine target point UCP1, and besides, discloses establishing and application of an obesity-resistant medicine high-flux screening model. Mainly a CRISPR / Cas9 system is related and utilized, two unique sgRNAs are designed, luciferase-T2A-tdTomato-WPRE-pA is knocked in after N end ATG of aUCP1 gene of cells, particularly luciferase and tdTomato are knocked in gene sites of immortalization brown fat cells UCP1, a first stably-transfected brown fat cell strain in which luciferase and tdTomato are inserted in a promoter region of the UCP1 is formed, and the first stably-transfected brown fat cell strain is applied to high-flux screening of obesity-resistant medicines, evaluation of the obesity-resistant medicines, evaluation of obesity-resistant active substances of organisms and development of a UCP1 detection reagent kit. The UCP1 is uncoupling protein specifically expressed atbrown fat tissue, and is an obesity-resistant new target point. The construction of the stably-transfected genetic engineering cell strain has important significance in the aspects of applying reportgenes and a high-connotation method, performing high-flux screening on a compound library acutely, accurately and efficiently, and obtaining obesity-resistant medicines capable of promoting thermogenesis and reducing weight.

The invention relates to an amphioxus uncoupling protein (UCP) molecule clone and the functional research in the biotechnology field. The invention clones uncoupling protein (UCP) gene from amphioxus firstly with degeneracy primer and 3', 5'-RACE, which expresses muscle, intestinal canal and gill widely. Heightening UCP expression on the third day with dealing in low temperature indicates UCP engaging in body heat regulation in low temperature; Reducing UCP expression with hungry for fourteen days indicates that UCP engages in energy metabolism regulation. UCP is related to many diseases as diabetes, cardiovascular disease, tumour and so on, so UCP can be produced medicines treating these diseases.

The present invention relates to methods for prevention and / or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.

The present invention is directed to compositions and methods related to the use of human OGC as an uncoupling protein.

This invention relates to molecular cloning of uncoupling protein (UCP) of Lampetra japonica. The UCP gene is cloned from Lampetra japonica with degenerate primer through 3',5'-RACE. UCP gene is associated with serveral diseases, such as diabetes mellitus, cardiovascular diseases and tumors. UCP gene can be used as a drug target for manufacturing drugs for treating above diseases.

The present invention concerns the design of a method for determining the activity of UCPs and which method can be used to evaluate the ability of different drugs to modify the activity of said proteins. These drugs may be used in the treatment of all diseases and conditions in which changes in thermogenic activity occur. Examples of these are obesity, fever, cachexia etc. Since the activity of the UCPs produces changes in the respiration rate, in the present method the activity of the UCPs is determined by monitoring the disappearance of NADH or NAD(P)H from the reduction in absorption between 300 and 380 nm or in fluorescence from 420-520 nm. In this method, these coenzymes are oxidised by the mitochondria of the yeast Saccharomyces cerevisiae in which different UCPs are expressed in a recombinant manner.

Genipin derivatives and pharmaceutical compositions thereof that inhibit the activity of uncoupling protein-2 (UCP2) and are useful in treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemia in a mammal are disclosed.

The physiological regulation of intake, growth and energy partitioning in animals is under the control of multiple genes, which may be important candidates for unraveling the genetic variation in economically relevant traits in beef production. The present invention relates to the identification of a single nucleotide polymorphisms (SNPs) within the bovine genes encoding growth hormone receptor (GHR), ghrelin, leptin, neuropeptide Y (NPY), and Uncoupling Protein 2 (UCP2) and their association with economically relevant traits in beef production. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable meat quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field locations.

The invention relates to a new application of a compound Compound C, which is the application of the compound Compound C in the preparation of a medicament for promoting the expression of adipocyte UCP1. The browning of adipocytes is promoted, that is, the expression of brown adipocytes marker gene uncoupling protein 1 (UCP1) is enhanced, excess fat can be effectively consumed in the form of calories, glucose uptake and fatty acid oxidation can be promoted, the number and vitality of mitochondria can be improved, and the levels of glucose and lipid metabolism and energy metabolism in the bodycan be enhanced, thereby effectively treating fatty liver, impaired glucose tolerance, insulin resistance and type 2 diabetes. Therefore, the compound Compound C has an effect of promoting the expression of the adipocyte UCP1, and can effectively prevent and treat the fatty liver, the impaired glucose tolerance, the insulin resistanceand the type 2 diabetes.

The invention provides novel application of Linifanib. The Linifanib has the functions of promoting browning of white adipocytes, promoting the expression of an uncoupling protein 1 (Ucp1), promotingmRNA expression levels of browning marker genes PrDm16, Pgcl alpha, Cidea, Dio2 and Cox8b, inhibiting preadipocytes to be differentiated into adipocytes and remarkably inhibiting the adipocytes to generate mRNA expressions of marker genes Ppar gamma, Cebp alpha and Ap2. Therefore, the Linifanib has the functions of promoting the browning of the adipocytes and inhibiting generation of the adipocytes, so that the Linifanib plays an important role in preventing and treating diseases related to fat metabolism and has a great application prospect in prevention and development of drugs of adiposis,diabetes mellitus, fatty liver and hyperlipidaemia.

The invention discloses a preparation method of rabbit anti-tree shew antiserum. The method comprises the steps of selecting an experimental animal, preparing serum, carrying out primary immunization and booster immunization and testing serum titer; the preparation method of the serum comprises the steps of collecting blood, stopping bleeding, preparing the serum and comparing the function of the serum; a bidirectional immune diffusion method is adopted by the test for the serum titer. According to the preparation method of the rabbit anti-tree shew antiserum, the content of tree shew uncoupling protein-1(UCP1) can be measured by the prepared antiserum, and the result error is generally within the range of 3-5%, so that the error range is reduced; after the steps of primary immunization and booster immunization are utilized, the production cost is lowered, the UCP1 content measurement effect is good, and the economic benefit is high.

A method using the extrat of capejasmine fruit to specifically suppress the uncoupling protein 2 (UCP 2) for improving the secretion of insulin and treating diabetes B includes such steps as decocting capejasmine fruit, extracting by macroreticular resin, diluting with alcohol, vacuum freeze-drying to obtain extract, and using it to culture the pancreatic island cells of mouse for obviously stimulating the secretion of insulin.

The invention provides a new application of Linifanib. Linifanib can promote the browning of white adipocytes, promote the expression of uncoupling protein 1 (Ucp1), and promote the mRNA expression levels of browning marker genes PrDm16, Pgclα, Cidea, Dio2, Cox8b, and at the same time, it can inhibit the differentiation of preadipocytes For mature adipocytes, it significantly inhibits the mRNA expression of adipogenic marker genes Pparγ, Cebpα and Ap2. It can be seen that Linifanib can not only promote the browning of adipocytes, but also inhibit the formation of adipocytes. It plays an important role in the prevention and treatment of fat metabolism related diseases, including the prevention and treatment of obesity, diabetes, fatty liver, hyperlipidemia and There are huge application prospects in drug development.

The invention relates to an application of norathyriol in treating type II diabetes, belonging to the technology field of biopharmaceuticals and molecular biology. After co-incubation of 293A cells and norathyriol for 24 hours, the expression level of uncoupling protein 2 (UCP2) coding gene in 293A cells is remarkably down-regulated. The invention discloses that the norathyriol can be used for inhibiting expression UCP2 gene in 293A cells and can be used for preparing drugs for preventing and treating type II diabetes; and proposes an in vitro test model for treating type II diabetes.

The invention discloses an application of UCP1 (uncoupling protein 1) to activity detection of human recombinant FGF21 (fibroblast growth factor 21) protein. Adipocytes subjected to induced differentiation are taken as objects, qRT-PCR (quantitative real-time polymerase chain reaction) is adopted to detect the rising degree of UCP1 gene expression level of the adipocytes processed by the human recombinant FGF21 protein with different concentrations, and the activity of the human recombinant FGF21 protein is determined. The invention discovers that the UCP1 expression level and the concentration of the used human recombinant FGF21 protein have a good dose-effect relationship, so that the UCP1 expression level of the adipocytes is determined to be a new index for activity detection of the human recombinant FGF21 protein. A method adopts a simple operation process, has low environmental requirement and has good practical value.

Disclosed is a method for screening a compound having an activity that selectively modulates an androgen receptor, comprising a step of measuring the mRNA expression level of prostate-specific antigen or the production level of prostate-specific antigen in prostate cancer cells by contacting a test substance with the prostate cancer cells, and a step of measuring the mRNA expression level of uncoupling protein 1 or the production level of uncoupling protein 1 in adipocytes by contacting a test substance with the adipocytes. Additionally disclosed is a selective androgen receptor modulator, comprising as an active ingredient thereof a compound represented by any of structural formulas (I) to (III), and a composition for preventing or treating a lifestyle-related disease, comprising as an active ingredient thereof said selective androgen receptor modulator.